Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial

View/Open
Volume
386
Pagination
2059 - 2068
DOI
10.1016/S0140-6736(15)00257-3
Journal
LANCET
Issue
10008
ISSN
0140-6736
Metadata
Show full item record
Authors
Williams, B; MacDonald, TM; Morant, S; Webb, DJ; Sever, P; McInnes, G; Ford, I; Cruickshank, JK; Caulfield, MJ; Salsbury, J
URI
http://qmro.qmul.ac.uk/xmlui/handle/123456789/19182
Collections
Licence information
Open Access article distributed under the terms of CC BY
Copyright statements
© Williams et al.